Melatonin and cerium oxide nanoparticles additively mitigate capecitabine-induced hepatotoxicity via targeting oxidative stress, apoptosis, and ERK signaling.

IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Khalid M Mohany, Heba M Elkady, Nashwa Hamad, Sahar E M El-Deek
{"title":"Melatonin and cerium oxide nanoparticles additively mitigate capecitabine-induced hepatotoxicity via targeting oxidative stress, apoptosis, and ERK signaling.","authors":"Khalid M Mohany, Heba M Elkady, Nashwa Hamad, Sahar E M El-Deek","doi":"10.1186/s40360-026-01150-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Capecitabine (CAP), a chemotherapy prodrug, is associated with a significant dose-limiting hepatotoxicity. This study evaluated the protective efficacy of melatonin (MEL) and cerium oxide nanoparticles (CeO₂ NPs) against CAP-induced toxicity.</p><p><strong>Methods: </strong>Fifty male Wistar rats were divided into five groups: control, CAP-only (500 mg/kg/week), CAP + MEL (10 mg/kg/day), CAP + CeO₂ NPs (30 mg/kg/day), and a combination therapy group (CAP + MEL + CeO₂ NPs). After a six-week treatment period, assessments included alanine and aspartate transaminases (ALT, AST); hepatic oxidative stress markers [glutathione peroxidase-1 (GPx-1), superoxide dismutase (SOD), and malondialdehyde (MDA)]; apoptotic markers [B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (BAX) mRNA, cleaved caspase-3 (c-caspase-3), and protein 53 (p53)]; pro-survival signaling [extracellular signal-regulated kinase (ERK1/2)]; and histopathological evaluation of liver tissue.</p><p><strong>Results: </strong>CAP administration induced significant liver damage, characterized by elevated ALT and AST, depletion of GPx-1 and SOD, increased MDA, and activation of the mitochondrial apoptotic pathway, indicated by an elevated BAX/Bcl-2 ratio and increased levels of p53 and c-caspase-3. This was accompanied by suppression of ERK1/2 signaling and severe histopathological alterations. Both MEL and CeO₂ NPs, significantly attenuated these deleterious effects. The combination therapy demonstrated a comparatively superior effect, resulting in a near-complete normalization of all measured parameters, including oxidative stress, apoptosis, ERK1/2 activity, and liver histoarchitecture.</p><p><strong>Conclusion: </strong>Melatonin and CeO₂ NPs provide hepatoprotection via distinct yet complementary mechanisms. Their combined administration presents a superior strategy to mitigate CAP-induced liver injury by concurrently counteracting oxidative stress, inhibiting apoptosis, and enhancing pro-survival signaling.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13262367/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40360-026-01150-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Capecitabine (CAP), a chemotherapy prodrug, is associated with a significant dose-limiting hepatotoxicity. This study evaluated the protective efficacy of melatonin (MEL) and cerium oxide nanoparticles (CeO₂ NPs) against CAP-induced toxicity.

Methods: Fifty male Wistar rats were divided into five groups: control, CAP-only (500 mg/kg/week), CAP + MEL (10 mg/kg/day), CAP + CeO₂ NPs (30 mg/kg/day), and a combination therapy group (CAP + MEL + CeO₂ NPs). After a six-week treatment period, assessments included alanine and aspartate transaminases (ALT, AST); hepatic oxidative stress markers [glutathione peroxidase-1 (GPx-1), superoxide dismutase (SOD), and malondialdehyde (MDA)]; apoptotic markers [B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (BAX) mRNA, cleaved caspase-3 (c-caspase-3), and protein 53 (p53)]; pro-survival signaling [extracellular signal-regulated kinase (ERK1/2)]; and histopathological evaluation of liver tissue.

Results: CAP administration induced significant liver damage, characterized by elevated ALT and AST, depletion of GPx-1 and SOD, increased MDA, and activation of the mitochondrial apoptotic pathway, indicated by an elevated BAX/Bcl-2 ratio and increased levels of p53 and c-caspase-3. This was accompanied by suppression of ERK1/2 signaling and severe histopathological alterations. Both MEL and CeO₂ NPs, significantly attenuated these deleterious effects. The combination therapy demonstrated a comparatively superior effect, resulting in a near-complete normalization of all measured parameters, including oxidative stress, apoptosis, ERK1/2 activity, and liver histoarchitecture.

Conclusion: Melatonin and CeO₂ NPs provide hepatoprotection via distinct yet complementary mechanisms. Their combined administration presents a superior strategy to mitigate CAP-induced liver injury by concurrently counteracting oxidative stress, inhibiting apoptosis, and enhancing pro-survival signaling.

褪黑素和氧化铈纳米颗粒通过靶向氧化应激、细胞凋亡和ERK信号传导,共同减轻卡培他滨诱导的肝毒性。
背景:卡培他滨(Capecitabine, CAP)是一种化疗前用药,具有显著的剂量限制性肝毒性。本研究评估了褪黑素(MEL)和氧化铈纳米颗粒(ceo_2 NPs)对cap诱导的毒性的保护作用。方法:将50只雄性Wistar大鼠分为5组,分别为对照组、单用CAP (500 mg/kg/周)、CAP + MEL (10 mg/kg/天)、CAP + CeO₂NPs (30 mg/kg/天)和联合治疗组(CAP + MEL + CeO₂NPs)。治疗6周后,评估包括丙氨酸和天冬氨酸转氨酶(ALT, AST);肝脏氧化应激标志物[谷胱甘肽过氧化物酶-1 (GPx-1)、超氧化物歧化酶(SOD)和丙二醛(MDA)];凋亡标志物[b细胞淋巴瘤2 (Bcl-2), Bcl-2相关X蛋白(BAX) mRNA,裂解caspase-3 (c-caspase-3)和蛋白53 (p53)];促生存信号通路[细胞外信号调节激酶(ERK1/2)];以及肝组织的组织病理学评估。结果:CAP诱导肝损伤显著,表现为ALT和AST升高,GPx-1和SOD缺失,MDA升高,线粒体凋亡通路激活,表现为BAX/Bcl-2比值升高,p53和c-caspase-3水平升高。这伴随着ERK1/2信号的抑制和严重的组织病理学改变。MEL和CeO 2 NPs都能显著减弱这些有害影响。联合治疗显示出相对优越的效果,导致所有测量参数几乎完全正常化,包括氧化应激、细胞凋亡、ERK1/2活性和肝脏组织结构。结论:褪黑素和CeO 2 NPs通过不同但互补的机制提供肝脏保护。这两种药物联合使用可以通过同时对抗氧化应激、抑制细胞凋亡和增强促生存信号传导来减轻cap诱导的肝损伤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY
CiteScore
4.80
自引率
0.00%
发文量
87
审稿时长
12 weeks
期刊介绍: BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书